CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
Inguinal lymph node fine needle aspirate biopsy +3 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02801942
NCT02801942N/ACompleted

Exploration of the Peripheral Immune System in Subjects With New Onset T1 Diabetes (NOT1D)

GlaxoSmithKline·interventional·Posted Jun 16, 2016·Updated Feb 27, 2019

In Brief

A clinical study evaluating Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, and 2 other interventions for Diabetes Mellitus, Type 1. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed in peripheral blood derived immune cells. Therefore this study will assess and compare the molecular immune profile of cells derived from the iLN in healthy and NOT1D subjects, to understand the immunological processes that may lead to beta cell destruction. It is a multi-center, non-drug treatment study. Up to 15 subjects in each group, namely healthy subjects and NOT1D subjects, will be evaluated in the study. A data look will be carried out after the recruitment of a cohort of up to 5 healthy subjects, to determine if the quality and quantity of cells derived from aspirate or core biopsy or from peripheral blood are likely to be sufficient to continue the study to meet its primary objective. An interim analysis will be carried out after the recruitment of 5 evaluable healthy subjects and 5 evaluable NOT1D subjects. The primary purpose of this interim analysis will be to facilitate decision making and study design for a potential follow-up interventional study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 16, 2016
Enrollment StartJul 25, 2016
Primary CompletionDec 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago

Interventions

Inguinal lymph node fine needle aspirate biopsyprocedure

Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.

Inguinal lymph node core biopsyprocedure

Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.

Peripheral blood collectionprocedure

Blood sample (30 mL) will be collected, to derive immune cells.

Pre- and post-biopsy questionnaireother

All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.